These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 1756095)

  • 41. Stereoselective pharmacokinetics and pharmacodynamics of disopyramide and its metabolite in rabbits.
    Horikawa M; Yasumuro M; Kanno M; Hanada K; Hashiguchi M; Ogata H
    J Pharm Pharmacol; 2001 Dec; 53(12):1621-8. PubMed ID: 11804392
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Enantioselective steady-state kinetics of unbound disopyramide and its dealkylated metabolite in man.
    Hasselström J; Enquist M; Hermansson J; Dahlqvist R
    Eur J Clin Pharmacol; 1991; 41(5):481-4. PubMed ID: 1761078
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In vitro and in vivo studies on the stereoselective pharmacokinetics and biotransformation of an (S)-(-)- and (R)-(+)-pyrazolotriazine sulfoxide in the male rat.
    Naito S; Nishimura M
    Xenobiotica; 2002 Jun; 32(6):491-503. PubMed ID: 12160482
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Disopyramide and N-monodesalkyl disopyramide in serum and breast milk.
    Ellsworth AJ; Horn JR; Raisys VA; Miyagawa LA; Bell JL
    DICP; 1989 Jan; 23(1):56-7. PubMed ID: 2718484
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In vivo interaction of the enantiomers of disopyramide in human subjects.
    Giacomini KM; Nelson WL; Pershe RA; Valdivieso L; Turner-Tamiyasu K; Blaschke TF
    J Pharmacokinet Biopharm; 1986 Aug; 14(4):335-56. PubMed ID: 3772736
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Stereoselective gastrointestinal clearance of disopyramide in rabbits treated with activated charcoal.
    Huang JD
    J Pharm Sci; 1988 Nov; 77(11):959-62. PubMed ID: 3225758
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Stereoselective biotransformation of cicletanine in cultured rat and human hepatocytes.
    Menard C; Lamiable D; Vistelle R; Morin E; Ratanasavanh D
    Pharmacol Res; 2000 Jul; 42(1):87-92. PubMed ID: 10860640
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of serum concentrations of disopyramide and its metabolite mono-N-dealkyldisopyramide on the anticholinergic side effects associated with disopyramide.
    Tsuchishita Y; Fukumoto K; Kusumoto M; Ueno K
    Biol Pharm Bull; 2008 Jul; 31(7):1368-70. PubMed ID: 18591776
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Stereoselective pharmacokinetics of disopyramide and interaction with cimetidine.
    Bonde J; Pedersen LE; Nygaard E; Ramsing T; Angelo HR; Kampmann JP
    Br J Clin Pharmacol; 1991 Jun; 31(6):708-10. PubMed ID: 1867965
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Pharmacokinetic study of disopyramide in normal man].
    Mallein R; Rondelet J; Boucherat M; Ksavrelof M; Pignat M
    Therapie; 1978; 33(4):463-73. PubMed ID: 734626
    [No Abstract]   [Full Text] [Related]  

  • 51. Determination of disopyramide and mono-N-desisopropyl-disopyramide in serum by gas-liquid chromatography with nitrogen-selective detection.
    Brien JF; Nakatsu K; Armstrong PW
    J Pharmacol Methods; 1983 Jun; 9(4):295-308. PubMed ID: 6621050
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Relative bioavailability of two disopyramide capsules in humans based on total, unbound, and unbound enantiomer concentrations.
    Takahashi H; Ogata H; Shimizu M; Hashimoto K; Masuhara K; Kashiwada K; Someya K
    Biopharm Drug Dispos; 1993 Jul; 14(5):409-18. PubMed ID: 8218959
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Disopyramide pharmacokinetics in the elderly after single oral administration.
    Roberto P; Vitaliano B; Donatella P; Raffaella M; Sergio B; Gabriella C
    Pharmacol Res Commun; 1988 Dec; 20(12):1025-34. PubMed ID: 3211990
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Kinetics of disopyramide in decreased hepatic function.
    Bonde J; Graudal NA; Pedersen LE; Balsløv S; Angelo HR; Svendsen TL; Kampmann JP
    Eur J Clin Pharmacol; 1986; 31(1):73-7. PubMed ID: 3780831
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Simultaneous assay of disopyramide and monodesisopropyldisopyramide enantiomers in biological samples by liquid chromatography.
    Le Corre P; Gibassier D; Sado P; Le Verge R
    J Chromatogr; 1988 Feb; 424(2):424-9. PubMed ID: 3372636
    [No Abstract]   [Full Text] [Related]  

  • 56. Comparative pharmacokinetics of unbound disopyramide enantiomers following oral administration of racemic disopyramide in humans.
    Takahashi H; Ogata H; Shimizu M; Hashimoto K; Masuhara K; Kashiwada K; Someya K
    J Pharm Sci; 1991 Jul; 80(7):709-11. PubMed ID: 1941574
    [No Abstract]   [Full Text] [Related]  

  • 57. Effect of ethanol intake on disopyramide elimination by healthy volunteers.
    Olsen H; Bredesen JE; Lunde PK
    Eur J Clin Pharmacol; 1983; 25(1):103-5. PubMed ID: 6617710
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Kinetics of disopyramide in decreased hepatic function.
    Belpaire FM; Bogaert MG
    Eur J Clin Pharmacol; 1987; 32(6):639. PubMed ID: 3653235
    [No Abstract]   [Full Text] [Related]  

  • 59. The influence of surgery on the elimination kinetics of disopyramide in pigs.
    Pedersen LE; Hermansen K; Olesen HO; Rasmussen SN
    Acta Pharmacol Toxicol (Copenh); 1986 Jul; 59(1):86-8. PubMed ID: 3766155
    [No Abstract]   [Full Text] [Related]  

  • 60. Pharmacokinetic consequences of product stereoselectivity in the metabolism of nafimidone: estimation of fraction metabolized.
    Kerr BM; Boddy AV; Moreland TA; Levy RH
    J Pharm Sci; 1991 Aug; 80(8):812-4. PubMed ID: 1791547
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.